Talwar Harvinder, Talreja Jaya, Samavati Lobelia
Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI.
Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine and Detroit Medical Center, Detroit, MI; Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, E. Canfield, Detroit, MI, USA.
Mycobact Dis. 2016 Jun;6(2). doi: 10.4172/2161-1068.1000214. Epub 2016 Jun 28.
One-third of the world's population is infected with tuberculosis, only 10% will develop active disease and the remaining 90% is considered to have latent TB (LTB). While active TB is contagious and can be lethal, the LTB can evolve to active TB. The diagnosis of TB can be challenging, especially in the early stages, due to the variability in presentation and nonspecific signs and symptoms. Currently, we have limited tools available to diagnose active TB, predict treatment efficacy and cure of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of protective immune responses through vaccination. Therefore, the identification of robust and accurate tuberculosis-specific biomarkers is crucial for the successful eradication of TB. In this commentary, we summarized the available methods for diagnosis and differentiation of active TB from LTB and their limitations. Additionally, we present a novel peptide microarray platform as promising strategy to identify TB biomarkers.
世界三分之一的人口感染了结核病,只有10%会发展为活动性疾病,其余90%被认为患有潜伏性结核(LTB)。虽然活动性结核病具有传染性且可能致命,但潜伏性结核可能会演变为活动性结核病。由于临床表现的变异性以及非特异性体征和症状,结核病的诊断可能具有挑战性,尤其是在早期阶段。目前,我们用于诊断活动性结核病、预测活动性结核病的治疗效果和治愈情况、潜伏性结核感染的再激活以及通过疫苗接种诱导保护性免疫反应的工具有限。因此,识别强大而准确的结核病特异性生物标志物对于成功根除结核病至关重要。在这篇评论中,我们总结了诊断和区分活动性结核病与潜伏性结核的现有方法及其局限性。此外,我们提出了一种新型肽微阵列平台,作为识别结核病生物标志物的有前景的策略。